Per the packet definition, the condition arises from a congenital defect, intestinal infarction, or extensive surgical resection of the intestinal tract, leaving a functional small intestine under 200 cm. No genes, inheritance pattern, or molecular mechanism are supplied in the packet, so a genetic basis is not certified here.

The packet supplies no diagnostic criteria or test list. The only measure it states is the definitional threshold of a functional small intestine shorter than 200 cm. Diagnostic approaches are otherwise not certified in this packet.

The packet lists teduglutide (brand GATTEX, NDA, FDA approval date 2012-12-21, market status ACTIVE) as a current FDA-approved option; an orphan-drug record from Takeda Pharmaceuticals U.S.A. gives the indication 'Treatment of short bowel syndrome.' The approved-treatment list also contains several somatropin products with market status ACTIVE, but the packet states no short bowel syndrome indication for them. Orphan-drug records describe Zorbtive (somatropin) and NutreStore as APPROVED for use in short bowel syndrome; their current market status is not given. Orphan designations (status DESIGNATED, which is not approval) include apraglutide, glepaglutide, crofelemer, and melatonin. Other management approaches are not certified in this packet.

The packet contains no natural-history, outcome, or survival information. Prognosis is not certified in this packet.

ClinicalTrials.gov data in the packet count 25 active trials and detail ten. Examples include glepaglutide (NCT07197944, Phase 3, recruiting; NCT07228403, Phase 3, active not recruiting; Zealand Pharma), apraglutide versus placebo in adults (NCT07742735, Phase 3, recruiting, VectivBio AG), and sonefpeglutide (NCT04775706, Phase 2, recruiting, Hanmi Pharmaceutical). A participant registry (NCT01990040, Shire) is also listed. Trial titles do not establish the interventions tested. The publication digest classifies 208 publications, most commonly reviews and meta-analyses.